TriangleNCT00683046 · STUDY IN CONTEXT
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
All patients were administered the following drugs; 1. Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3 2. Melphalan 140mg/m2 IV on day -2 3. Stem cell infusion on day 0 4. Campath 20mg IV on day -7,-6,-5,-4, and -3
All patients were administered the following drugs; 1. Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3 2. Melphalan 140mg/m2 IV on day -2 3. Stem cell infusion on day 0 4. Campath 20mg IV on day -7,-6,-5,-4, and -3
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-lymphoid-leukemia
- nct id
- NCT00683046
- trial label
- T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
- applicability
- narrower
- applicability note
- Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 2
- harms Count
- 1
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-lymphoid-leukemia
- nct id
- NCT00683046
- outcome key
- om-0000
- source section id
- NCT00683046-om-0000
- source outcome index
- 0
- endpoint
- Median Disease-free Survival
- endpoint definition
- All patients were administered the following drugs; 1. Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3 2. Melphalan 140mg/m2 IV on day -2 3. Stem cell infusion on day 0 4. Campath 20mg IV on day -7,-6,-5,-4, and -3
- time origin
- Patients evaluated continuously with disease specific re-evaluation at day 30, 3 months, 6 months, 1 year, and as indicated thereafter up to 10 years
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-lymphoid-leukemia
- nct id
- NCT00683046
- outcome key
- om-0001
- source section id
- NCT00683046-om-0001
- source outcome index
- 1
- endpoint
- Median Overall Survival
- endpoint definition
- All patients were administered the following drugs; 1. Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3 2. Melphalan 140mg/m2 IV on day -2 3. Stem cell infusion on day 0 4. Campath 20mg IV on day -7,-6,-5,-4, and -3
- time origin
- Patients evaluated continuously with disease specific re-evaluation at day 30, 3 months, 6 months, 1 year, and as indicated thereafter up to 10 years
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-lymphoid-leukemia
- nct id
- NCT00683046
- outcome key
- om-0000
- arm key
- OG000
- arm label
- T-cell Depleted Allogeneic Stem Cell Transplantation
- regimen
- All patients were administered the following drugs; 1. Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3 2. Melphalan 140mg/m2 IV on day -2 3. Stem cell infusion on day 0 4. Campath 20mg IV on day -7,-6,-5,-4, and -3
- analyzed count
- 204
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00683046-om-0000#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-lymphoid-leukemia
- nct id
- NCT00683046
- outcome key
- om-0001
- arm key
- OG000
- arm label
- T-cell Depleted Allogeneic Stem Cell Transplantation
- regimen
- All patients were administered the following drugs; 1. Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3 2. Melphalan 140mg/m2 IV on day -2 3. Stem cell infusion on day 0 4. Campath 20mg IV on day -7,-6,-5,-4, and -3
- analyzed count
- 204
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00683046-om-0001#groups/OG000
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-lymphoid-leukemia
- nct id
- NCT00683046
- harm key
- EG000
- source section id
- NCT00683046-ae
- event group key
- EG000
- event group label
- T-cell Depleted Allogeneic Stem Cell Transplantation
- serious affected
- 69
- serious at risk
- 204
- other affected
- 0
- other at risk
- 204
- frequency threshold
- 5
- collection period
- 180 days
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice